These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 25468648)

  • 1. First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient.
    Fox JE; Volpe L; Bullaro J; Kakkis ED; Sly WS
    Mol Genet Metab; 2015 Feb; 114(2):203-8. PubMed ID: 25468648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vestronidase alfa: Recombinant human β-glucuronidase as an enzyme replacement therapy for MPS VII.
    Cadaoas J; Boyle G; Jungles S; Cullen S; Vellard M; Grubb JH; Jurecka A; Sly W; Kakkis E
    Mol Genet Metab; 2020 May; 130(1):65-76. PubMed ID: 32192868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII.
    Wang RY; da Silva Franco JF; López-Valdez J; Martins E; Sutton VR; Whitley CB; Zhang L; Cimms T; Marsden D; Jurecka A; Harmatz P
    Mol Genet Metab; 2020 Mar; 129(3):219-227. PubMed ID: 32063397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of vestronidase alfa enzyme replacement therapy in pediatric subjects < 5 years with mucopolysaccharidosis VII.
    Lau HA; Viskochil D; Tanpaiboon P; Lopez AG; Martins E; Taylor J; Malkus B; Zhang L; Jurecka A; Marsden D
    Mol Genet Metab; 2022 May; 136(1):28-37. PubMed ID: 35331634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials.
    Qi Y; McKeever K; Taylor J; Haller C; Song W; Jones SA; Shi J
    Clin Pharmacokinet; 2019 May; 58(5):673-683. PubMed ID: 30467742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease characteristics, effectiveness, and safety of vestronidase alfa for the treatment of patients with mucopolysaccharidosis VII in a novel, longitudinal, multicenter disease monitoring program.
    Giugliani R; Gonzalez-Meneses A; Scarpa M; Burton B; Wang R; Martins E; Oussoren E; Hennermann JB; Chabrol B; Grant CL; Sun A; Durand C; Hetzer J; Malkus B; Marsden D; Merritt Ii JL
    Orphanet J Rare Dis; 2024 May; 19(1):189. PubMed ID: 38715031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lentiviral-mediated gene therapy results in sustained expression of β-glucuronidase for up to 12 months in the gus(mps/mps) and up to 18 months in the gus(tm(L175F)Sly) mouse models of mucopolysaccharidosis type VII.
    Derrick-Roberts AL; Pyragius CE; Kaidonis XM; Jackson MR; Anson DS; Byers S
    Hum Gene Ther; 2014 Sep; 25(9):798-810. PubMed ID: 25003807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy.
    Vogler C; Levy B; Galvin NJ; Thorpe C; Sands MS; Barker JE; Baty J; Birkenmeier EH; Sly WS
    Pediatr Res; 1999 Jun; 45(6):838-44. PubMed ID: 10367775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vestronidase Alfa: A Review in Mucopolysaccharidosis VII.
    McCafferty EH; Scott LJ
    BioDrugs; 2019 Apr; 33(2):233-240. PubMed ID: 30848434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans.
    de Ru MH; van der Tol L; van Vlies N; Bigger BW; Hollak CE; Ijlst L; Kulik W; van Lenthe H; Saif MA; Wagemans T; van der Wal WM; Wanders RJ; Wijburg FA
    J Inherit Metab Dis; 2013 Mar; 36(2):247-55. PubMed ID: 22991166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival.
    Vogler C; Sands MS; Levy B; Galvin N; Birkenmeier EH; Sly WS
    Pediatr Res; 1996 Jun; 39(6):1050-4. PubMed ID: 8725268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First Report of a Patient with MPS Type VII, Due to Novel Mutations in
    Dubot P; Sabourdy F; Plat G; Jubert C; Cancès C; Broué P; Touati G; Levade T
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Missense models [Gustm(E536A)Sly, Gustm(E536Q)Sly, and Gustm(L175F)Sly] of murine mucopolysaccharidosis type VII produced by targeted mutagenesis.
    Tomatsu S; Orii KO; Vogler C; Grubb JH; Snella EM; Gutierrez MA; Dieter T; Sukegawa K; Orii T; Kondo N; Sly WS
    Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14982-7. PubMed ID: 12403825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease.
    Vogler C; Sands MS; Galvin N; Levy B; Thorpe C; Barker J; Sly WS
    J Inherit Metab Dis; 1998 Aug; 21(5):575-86. PubMed ID: 9728337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Numerous transcriptional alterations in liver persist after short-term enzyme-replacement therapy in a murine model of mucopolysaccharidosis type VII.
    Woloszynek JC; Roberts M; Coleman T; Vogler C; Sly W; Semenkovich CF; Sands MS
    Biochem J; 2004 Apr; 379(Pt 2):461-9. PubMed ID: 14705966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice.
    Montaño AM; Oikawa H; Tomatsu S; Nishioka T; Vogler C; Gutierrez MA; Oguma T; Tan Y; Grubb JH; Dung VC; Ohashi A; Miyamoto K; Orii T; Yoneda Y; Sly WS
    Mol Genet Metab; 2008 Jun; 94(2):178-89. PubMed ID: 18359257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function.
    O'Connor LH; Erway LC; Vogler CA; Sly WS; Nicholes A; Grubb J; Holmberg SW; Levy B; Sands MS
    J Clin Invest; 1998 Apr; 101(7):1394-400. PubMed ID: 9525982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral manifestations in patients and dogs with mucopolysaccharidosis Type VII.
    Kantaputra PN; Smith LJ; Casal ML; Kuptanon C; Chang YC; Nampoothiri S; Paiyarom A; Veerasakulwong T; Trachoo O; Ketudat Cairns JR; Chinadet W; Tanpaiboon P
    Am J Med Genet A; 2019 Mar; 179(3):486-493. PubMed ID: 30653816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical evidence for superior correction of neuronal storage by chemically modified enzyme in murine mucopolysaccharidosis VII.
    Huynh HT; Grubb JH; Vogler C; Sly WS
    Proc Natl Acad Sci U S A; 2012 Oct; 109(42):17022-7. PubMed ID: 23027951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy improves reproductive performance in mucopolysaccharidosis type VII mice but does not prevent postnatal losses.
    Soper BW; Pung AW; Vogler CA; Grubb JH; Sly WS; Barker JE
    Pediatr Res; 1999 Feb; 45(2):180-6. PubMed ID: 10022587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.